アトリウム・セラピューティクス
Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.18 | $3M | -$4M |
| 2026 Q1 | -0.97 | $20M | -$33M |
| 2025 Q4 | -1.70 | $859,000 | -$20M |
| 2025 Q3 | 0.00 | $0 | — |